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Key questions
What is already known about this subject?
 ► Iron deficiency is increasingly recognised as an 
important comorbidity in heart failure and impacts 
patient well- being. Most data on diagnosis and sub-
sequent treatment have been garnered from ambu-
latory patients with chronic heart failure, and there 
is a relative paucity of information relating to those 
with acute heart failure.
What does this study add?
 ► In this retrospective cohort study, we analysed 
Hospital Episode Statistics data characterising the 
prevalence of iron deficiency and/or iron deficiency 
anaemia in all 78 805 adults admitted to hospitals 
across England with a primary diagnosis of heart 
failure across a single calendar year. Overall, 91% 
of these patients required an unplanned hospital 
admission due to an acute heart failure syndrome.
 ► We describe the demographics typical of this co-
morbid population, and the associated outcomes 
with respect to mortality, readmission rates, length 
of stay and costs.
How might this impact on clinical practice?
 ► This study addresses knowledge gaps relating to 
the prevalence and impact of iron deficiency with 
or without anaemia in acute heart failure patients. 
As this data emanated from people presenting with 
a common ambulatory care sensitive condition, and 
treated by clinicians imbued with a range of clinical 
expertise working in the real- world clinical milieu, 
this information is germane to routine practice, and 
generalisable to similar populations and organisa-
tional models.
AbstrAct
Objectives Iron deficiency (ID), with or without anaemia 
(IDA), is an important comorbidity in people with chronic 
heart failure (HF), but the prevalence and significance 
in those admitted with HF is uncertain. We assessed 
the prevalence of ID or IDA in adults (age ≥21 years) 
hospitalised with a primary diagnosis of HF, and examined 
key metrics associated with these secondary diagnoses.
Methods A retrospective cohort study of Hospital Episode 
Statistics describing all adults admitted to National Health 
Service (NHS) hospitals across England from April 2015 
through March 2016 with primary diagnostic discharge 
coding as HF, with or without subsidiary coding for ID/IDA.
Results 78 805 adults were admitted to 177 NHS 
hospitals with primary coding as HF: 26 530 (33.7%) with 
secondary coding for ID/IDA, and 52 275 (66.3%) without. 
Proportionately more patients coded ID/IDA were admitted 
as emergencies (94.8% vs 87.6%; p<0.0001). Tending 
to be older and female, they required a longer length of 
stay (15.8 vs 12.2 days; p<0.0001), with higher per capita 
costs (£3623 vs £2918; p<0.0001), the cumulative excess 
expenditure being £21.5 million. HF- related (8.2% vs 
5.2%; p<0.0001) and all- cause readmission rates (25.8% 
vs 17.7%; p<0.05) at ≤30 days were greater in those with 
ID/IDA against those without, and they manifested a small 
but statistically significant increased inpatient mortality 
(13.5% v 12.9%; p=0.009).
Conclusions For adults admitted to hospitals in 
England, principally with acute HF, ID/IDA are significant 
comorbidities and associated with adverse outcomes, both 
for affected individuals, and the health economy.
IntROduCtIOn
Heart failure, iron deficiency and anaemia
It is estimated about 900 000 people are 
living with heart failure (HF) in the UK, this 
burdensome life- limiting syndrome arising 
from diverse aetiological cardiovascular 
conditions leading to systolic and diastolic 
ventricular dysfunction.1 Iron, an essential 
micronutrient, is fundamental to many meta-
bolic pathways, including the high energy 
biochemical reactions required of cardiac 
and skeletal muscle. In recent years iron defi-
ciency (ID) has been increasingly recognised 
in those with HF. Associated with negative 
outcomes in reduced quality of life, impaired 
functional capacity and a poor prognosis, this 
has emerged as a meaningful therapeutic 
target.2 3
The complex pathophysiology remains 
incompletely understood, but potential 
mechanisms of ID or iron deficiency anaemia 
(IDA) in HF include nutritional iron or 
vitamin deficiencies, and bone marrow 
hypoperfusion or dysfunction. ID may also 
stem from occult or overt blood loss, some-
times linked to anti- platelet or anticoagulant 
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medication, or through the effects of guideline- directed 
HF therapies. Angiotensin- converting- enzyme inhibitors, 
angiotensin- receptor- blockers, and some β-blockers such 
as carvedilol may inhibit erythropoiesis.4 5 In contrast, the 
mineralocorticoid receptor antagonist spironolactone 
may be beneficial in down- regulating hepcidin, a key 
modulator of iron homeostasis.6
While the above drugs are predominantly used for HF 
with a reduced ejection fraction (HFrEF), all HF subtypes 
as described in the European Society of Cardiology (ESC) 
guidelines exhibit this significant comorbidity.7 A preva-
lence of 53% for ID was noted in a single- centre study of 
1197 chronic HF patients, this diagnosed in 50%, 61% 
and 64% of those characterised with HFrEF, a mid- range 
EF (HFmrEF), and a preserved EF (HFpEF), respectively.8
Clinical setting
Despite the demonstrable adverse effects, policies on 
systematic screening and subsequent treatment of HF 
patients with ID or IDA remain inconsistent. Guidelines 
issued by the National Institute for Health and Care 
Excellence constitute the standards for treating HF for 
residents in England. In their latest guidance (NG106) 
of September 2018, pending the results of ongoing clin-
ical trials, concern was expressed about the cost effective-
ness of comprehensively assessing all HF patients beyond 
those with anaemia or HFrEF, and the awareness of non- 
specialists to consider and test for ID was questioned.9
The course of HF is unique to each individual. However 
those affected tend to progressively decline along a 
roller- coaster disease trajectory punctuated by increas-
ingly frequent hospital admissions. These HF admissions 
afford the opportunity to assess the frequency and impact 
of ID, but such data for England are lacking. Thus, we 
undertook a retrospective cohort study to evaluate the 
prevalence, clinical significance, and healthcare costs 
associated with the concurrent diagnoses of ID or IDA 
in people admitted to hospitals across England with a 
primary diagnosis of HF, their care often supervised by 
general physicians.
MetHOds
data sources
This study is based on Hospital Episode Statistics 
Admitted Patient Care (HES APC) data. The HES data 
warehouse, curated by the National Health Service 
(NHS) Information Centre for Health and Social Care, 
collates information on clinical activity relating to all 
NHS hospitals in England.10 For inpatients, as well as 
admission and discharge dates, this comprehensive data 
set includes individual patient- level demographics and 
clinical information such as age, gender and ethnicity, 
place of residence, diagnoses and any relevant diagnostic, 
medical or surgical procedures. HES data are pseudoan-
onymised, manifest in the generation of a bespoke set of 
32 alphanumeric characters by the application of a three- 
pass algorithm to a cluster of patient- specific information 
fields. This PSEUDO- HESID prevents individual patient 
identification but provides data useful to national govern-
ment bodies and regulators, including NHS England and 
the Department of Health. Data are also made available 
to researchers. For this study, aggregated HES APC data 
were accessed through a licenced commercial organisa-
tion, Harvey Walsh Ltd, reused with permission of NHS 
Digital (copyright 2019, all rights reserved).
diagnostic attribution and coding
The HES APC data set incorporates post- discharge diag-
nostic coding as designated by health informatics profes-
sionals trained to national standards, with oversight by 
local hospital clinicians, the degree of such supervision 
varying both within and between institutions. There is no 
other national data set against which to compare diag-
nostic coding accuracy, but as HES coding is the basis of 
reimbursement and benchmarking of healthcare organ-
isations, this has driven improved accuracy and depth of 
coding in recent years. Until April 2017, HES coding was 
subject to centralised national external audit, thereafter, 
this responsibility has been assumed by locality- based 
NHS provider trusts and Clinical Commissioning Groups.
A systematic review of discharge coding accuracy 
suggests this is robust and applicable to research activity.11 
Coding precision pertains particularly to the primary 
admission diagnosis, especially for conditions such as HF 
where the clinical features are relatively stereotyped, and 
there are supportive confirmatory tests such as natriuretic 
peptide assays and echocardiography. A recent audit 
comparing the concordance of clinicians’ and coders’ 
diagnoses reported a coding error rate of only 1.8% for 
those admitted with acute HF, this estimated at 10.5% 
across a range of secondary diagnoses.12 Documentation 
and information transfer relating to comorbidities tends 
to be more ambiguous, and specific evidence relating to 
the coding accuracy for ID or IDA is currently unavailable.
For the present study, codes utilised to define HF, ID 
or IDA were from the 10th revision of the International 
Statistical Classification of Diseases and Related Health 
Problems (ICD-10).13 There are 71 ICD-10 codes speci-
fying the clinical spectrum of anaemia. Clinical coders 
cannot assume the patient has ID or IDA unless so docu-
mented in the clinical record by the responsible clinician, 
and they are not permitted to independently interpret 
test results of any kind. As defined in the national clin-
ical coding standards,14 ‘iron deficiency’ is an Essential 
Modifier which requires that IDA must be extant in the 
clinical record for the applicable codes to be assigned. 
If IDA is not formally recorded in a form interpretable 
by coders, the coding rules stipulate that the diagnosis 
must be coded as D649: anaemia, unspecified. For this 
study, the ICD-10 codes used to differentiate HF patients 
with or without ID or IDA are listed in table 1. Consis-
tent with the coding convention described above, we 
also included ICD-10 code D649 within the IDA coding 
envelope, anticipating that a proportion of HF patients 
with IDA would be assigned that diagnostic code given 
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Table 1 ICD-10 codes used to identify patients with HF 
with or without ID/IDA
HF codes (primary diagnosis)
ID/IDA codes (secondary 
diagnoses)
I11.0 (hypertensive heart disease with 
(congestive) heart failure)
I25.5 (ischaemic cardiomyopathy)
I42.0 (dilated cardiomyopathy)
I42.9 (cardiomyopathy, unspecified)
I50.0 (congestive heart failure)
I50.1 (left ventricular failure)
I50.9 (heart failure, unspecified)
D500 (IDA secondary to blood 
loss (chronic))
D508 (other IDA)
D509 (IDA unspecified)
D649 (anaemia unspecified)
HF, heart failure; ICD-10, 10th revision of the International 
Statistical Classification of Diseases and Related Health Problems; 
ID, iron deficiency; IDA, iron deficiency anaemia.
Table 2 Hospital admissions with a primary diagnosis of heart failure in England in 2015/2016
N Age range
Overall
Emergency
(non- elective) Elective Day cases
Patients Spells Patients* Spells Patients* Spells Patients* Spells
With secondary ID/IDA ≥21 years 26 530 33 711 25 160 30 584 1063 1146 991 1981
≥75 years 19 312 23 918 18 654 22 291 542 573 434 1054
Without secondary ID/IDA ≥21 years 52 275 62 064 45 784 52 478 3581 3789 4492 5797
≥75 years 33 402 38 747 31 287 35 475 1365 1438 1328 1834
*Patients could be counted in more than one column for emergency, elective and day case admissions if they required more than one type of 
admission during the period analysed.
ID, iron deficiency; IDA, iron deficiency anaemia.
the expected variation in documentation and resultant 
coding practice.
study population
Iron deficiency was highlighted in the updated ESC HF 
guidelines of June 2016.2 Aware that this publication 
might engender transient changes in clinical practice 
and introduce random error, we elected to assess HES 
data for the financial year April 2015 through March 
2016. This evaluation relates to all adult men and women 
admitted over that period for whom HF was coded as the 
primary discharge diagnosis, with possible recording of 
ID or IDA in any of 19 subsidiary diagnostic coding posi-
tions.
Mindful that in a higher proportion of younger people, 
HF would stem from cyanotic congenital heart disease 
with secondary polycythaemia, a distinctive disruption 
of iron homeostasis which might disproportionately 
confound assessment of ID or IDA compared with the 
general HF population, we chose to define adulthood as 
 ≥ 21 years. In accepting this compromise, data on only 
41 patients aged 18 to 20 years admitted over the above 
period were excluded from study evaluation.
Analyses
In HES data, a hospital admission is classified as a ‘spell’, 
defined as a period of continuous inpatient care on the 
premises of a single healthcare provider. Transfer to 
another hospital for further care or rehabilitation would 
start a new spell, and linking consecutive inpatient spells 
would constitute a ‘superspell’. Markers of sequential 
inpatient spells are not routinely logged on HES data.15 
Therefore, for the purpose of this study, we elected to 
undertake evaluation of the HES APC data extract 
relating to the first hospital spell.
The following analyses were undertaken for the year 
specified: total number of HF admissions; patients’ 
gender and age; type of admission – emergency (non- 
elective), elective, or day case; ≤30 days unplanned 
readmission rate under the same HF- related primary diag-
nostic ICD-10 code; ≤30 days all- cause unplanned read-
mission rate; length of stay (LOS) of the initial hospital 
spell; inhospital mortality rate. We compared direct costs 
associated with these HF admissions for patients with and 
without secondary coded diagnoses of ID or IDA based 
on the NHS National Tariff Payment System for the 2015 
to 2016 financial year.
statistical methods
X2 testing was used to examine the independence of cate-
gorical variables linked to HF admissions. For continuous 
variables, the independent t- test was utilised to assess 
whether differences between group means achieved statis-
tical significance. Significance was accepted at the p<0.05 
level. Descriptive statistics are provided throughout.
Results
Between April 2015 through March 2016, 78 805 adults 
with a primary diagnosis of HF were admitted to 177 NHS 
acute provider hospitals throughout England. Of these, 
26 530 (33.7%) had a documented secondary diagnosis 
of ID or IDA, while 52 275 (66.3%) did not (table 2). For 
these HF patients, 12 690 were coded as exhibiting ID and 
6840 coded IDA as single diagnostic categories. Coding 
for both ID and IDA was evident in 7000 patients. To avoid 
double counting, we excluded one of these duplicated 
records from analysis. Given the extent of joint coding 
for ID and IDA (26.3%), and without specific informa-
tion on the laboratory tests differentiating between these 
diagnostic subgroups, we chose to pool data relating to 
those coded for either ID, IDA or these in combination, 
copyright.
 on June 10, 2020 at S
w
ansea U
niversity. P
rotected by
http://openheart.bm
j.com
/
O
pen H
eart: first published as 10.1136/openhrt-2019-001153 on 11 M
arch 2020. D
ow
nloaded from
 
Open Heart
4 Beattie JM, et al. Open Heart 2020;7:e001153. doi:10.1136/openhrt-2019-001153
Figure 1 Distribution of ages in HF patients with and without a secondary diagnosis of ID/IDA.
Table 3 Summary of heart failure admission data
Analysis
All HF patients aged ≥21 years n=78 805 All HF patients aged ≥75 years n=52 714
With ID/
IDA
Without 
ID/IDA
RR
(95% CI) P value
With ID/
IDA
Without 
ID/IDA
RR
(95% CI) P value
Proportion with 
emergency admissions
94.8% 87.6% 1.08
(1.07 to 1.09)
p<0.0001 96.6% 93.7% 1.03
(1.02 to 1.04)
p<0.0001
Heart failure readmission 
rate ≤30 days*
8.2% 5.2% 1.59
(1.50 to 1.68)
p<0.0001 7.7% 5.5% 1.47
(1.41 to 1.54)
p<0.0001
All- cause readmission 
rate ≤30 days
25.8% 17.7% 1.46
(1.42 to 1.50)
p<0.05 25.3% 18.7% 1.35
(1.31 to 1.40)
p<0.05
*Under the same ICD-10 HF code.13
HF, heart failure; ICD-10, 10th revision of the International Statistical Classification of Diseases and Related Health Problems; ID, iron 
deficiency; IDA, iron deficiency anaemia; RR, Relative risk.
as a single clinical descriptor (ID/IDA) with respect to 
subsequent analyses.
demographics
The majority of HF patients coded with ID/IDA were 
female compared with those without this secondary 
coding (50.2% vs 45.0%, respectively; p<0.0001). Mean 
age also differed significantly between the two groups: 
79.1 years (range: 21 to 105) versus 76.6 years (range: 21 
to 106) for those with and without a secondary diagnosis 
of ID/IDA, respectively (p<0.0001). The distribution of 
patient ages for each group is shown in figure 1.
Classification of admissions
For all of these HF admissions, 91.2% were classified as 
emergency, the remainder being categorised as elective 
for diagnostic investigation or to facilitate provision of 
treatment elements consistent with contemporary HF 
therapy. Among HF patients exhibiting secondary ID/
IDA coding, 94.8% (n=25 160/26 530) had emergency 
admissions compared with 87.6% for those without this 
designation (n=45 784/52 275; p<0.0001).
Readmission rates
Heart failure patients with a secondary diagnosis of ID/
IDA had both higher ≤30 day HF- related and all- cause 
readmission rates compared with those without: 8.2% 
versus 5.2%, (difference: 3.0% (95% CI: 2.64 to 3.40); 
p<0.0001), and 25.8% versus 17.7%, (difference: 8.1% 
(95% CI: 7.49 to 8.73); p<0.05), respectively. Table 3 
shows admission data for the whole study cohort, and also 
the results of a subanalysis for patients aged ≥75 years at 
the time of initial admission.
length of stay and costs
For emergency admissions, the mean LOS was longer 
for patients with a supplementary diagnosis of ID/IDA 
compared with those without (15.8 vs 12.2 days). The 
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Figure 2 Length of stay and age for HF patients with and without a secondary diagnosis of ID/IDA.
inter- group difference of 3.6 days was statistically signif-
icant (95% CI: 3.32 to 3.80; p<0.0001). The difference 
in mean LOS between HF patients with and without ID/
IDA was maintained across all age groups (figure 2). 
For the 30 584 emergency hospital spells recorded for 
HF patients with a secondary diagnosis of ID/IDA, this 
equates to an additional 108 946 bed- days.
The mean estimated cost associated with emergency 
hospital admissions was higher among HF patients 
with secondary diagnostic coding of ID/IDA compared 
with those without (£3623 vs £2918, respectively) which 
equates to a per capita excess of £705 for patients so 
described (95% CI: £662 to £748; p<0.0001). This addi-
tional expenditure summates to £21.5 million across the 
English health economy for HF patients admitted with 
this secondary coding during the 2015 to 2016 financial 
year.
Correction for age showed that this was not a significant 
covariate in relation to the classification of admissions, 
readmission rates, LOS or cost. Our analyses are based 
on aggregated data, therefore it is not possible to provide 
sex- standardised results with respect to these metrics.
Mortality
There was a small but statistically significant greater 
inhospital mortality rate for HF patients with ID/
IDA versus those without, 13.5% (n=3592) and 12.9% 
(n=6730), respectively (95% CI: 0.16 to 1.17; relative risk 
1.05 (95% CI: 1.01 to 1.09); p=0.009). Importantly, while 
this observation is based on documentation of patients 
having died in hospital, the cause of death is not defined 
within the HES data set, and we had no access to the 
applicable Office for National Statistics death registration 
data. Therefore, it cannot be concluded, nor should it be 
assumed, that these deaths were specifically attributable 
to the primary admission diagnosis of HF.
Comorbidities
Acute kidney injury or chronic kidney disease (CKD) are 
common comorbidities in HF patients. We compared the 
relative distribution of CKD in HF patients exhibiting ID/
IDA or no ID/IDA based on any additional ICD-10 diag-
nostic coding as N183 (Stage 3 CKD; estimated glomer-
ular filtration rate 30 to 49 mL/min/1.73 m2). There was 
a significant association between ID/IDA coding and 
coding for CKD, 12.6% (n=3349), against 8.3% (n=4354) 
for the non- ID/IDA group (95% CI: 3.8 to 4.8; p<0.002).
While ID in HF patients has been linked to gastroin-
testinal malignancy,16 for this study population there 
were no discernible differences between the ID/IDA and 
non- ID/IDA groups with respect to the relative frequency 
of coding for these diagnoses or other conditions associ-
ated with blood loss such as peptic ulcer disease in the 
index HF admission, or for any subsequent admission 
over a 90- day period thereafter.
dIsCussIOn
The results of our analyses derive from HES data charac-
terising all adults admitted with a primary diagnosis of HF 
to every NHS provider hospital in England over the speci-
fied period. We note that the mean age of this unselected 
real- world clinical cohort is typical of those admitted with 
HF in the UK.1 People with a secondary diagnosis of ID/
IDA were significantly older and more commonly female, 
and a relative preponderance of female HF patients 
exhibiting ID or IDA has been previously described.17 18
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We noted that HF admissions coded with a secondary 
diagnosis of ID/IDA were longer and more expensive 
than those without such diagnoses, these associations 
persisting across the age range. Comparable to our data, 
Caughey and colleagues found that for 6291 HF patients 
hospitalised in the USA, the presence of anaemia, 
defined by the WHO as a haemoglobin <13 g/L for men 
and <12 g/L for women, disproportionately increased 
LOS by 3.5 days for those with HFpEF, who also tended 
to be older and female, against 1.8 days for their counter-
parts with HFrEF.19 20
Patients with ID/IDA appeared to be at higher risk of 
early readmission, and the inhospital mortality rate was 
greater at 13.5% for HF patients with these secondary 
codes compared with 12.9% for those without. These 
mortality rates are similar to those documented at 13.3% 
and 12.6% for HF patients treated on elderly care wards 
or without specialist HF input, respectively, as reported 
in the relevant iteration of the National Heart Failure 
Audit (NHFA) for England and Wales, which included 
82% of all HF patients admitted in England during this 
study period.21 For that audit cycle, only 46% of patients 
were admitted to cardiology wards, the majority being 
treated on non- specialist wards. Of data submitted to 
the 2015/2016 NHFA, 68.3% were characterised as 
pertaining to patients with HFrEF. HF subtypes are 
not differentiated in the HES database, and at present, 
data on ID or IDA are not logged on the NHFA system. 
However, the recently established linkage of information 
archived in these national data repositories, intended to 
facilitate a more in- depth study of the acute HF popu-
lation (NCT03733665 ( ClinicalTrials. gov identifier)), 
might provide the opportunity for triangulation.
While 33.7% of these hospital admissions with a primary 
diagnostic coding of HF included ID/IDA in a subsidiary 
coding position, this figure is less than the approximately 
50% previously reported for HF patients.2 8 22 23 However, 
most studies describing this association have involved 
ambulant patients with chronic HF. By contrast, the 
vast majority of those constituting the basis of this study 
required emergency admission, inferring they exhibited 
de novo acute HF or acute decompensation of chronic HF. 
To date there is a relative paucity of data relating to ID or 
IDA in patients presenting with these clinical scenarios, 
and accepted measures of assessment might be compro-
mised by the pathophysiological responses intrinsic to 
the acute HF state.24
HF patients may exhibit absolute or functional ID, 
the former reflecting depleted iron stores. With func-
tional ID, iron stores are replete, but stored iron traf-
ficking is suppressed and too ineffectual to drive normal 
erythropoiesis or maintain cellular metabolic function.3 
Under normal physiological conditions, serum ferritin 
correlates well with body iron stores, hence, is used as a 
proxy measure of iron status. By convention, but largely 
based on assessing those with chronic HF, a serum ferritin 
<100 ng/mL has been adopted as the cut point defining 
absolute ID. Similarly, functional ID in HF is delineated 
as a serum ferritin of 100 to 299 ng/mL with a transferrin 
saturation (TSAT) <20%.7 However, ferritin reacts as an 
acute phase protein and increases in response to inflam-
mation and oxidative stress.17 Conversely, transferrin is 
a negative acute phase reactant, and may be suppressed 
under these conditions.25 Thus dilemmas exist in the 
diagnosis of ID in the acute HF setting.
Jankowska and colleagues found that only 34% of 165 
patients presenting with acute HF fulfilled the diagnostic 
criteria for ID based on the ferritin and TSAT levels 
described above.26 This group compared those results with 
other potentially more robust tests of ID, these defined as 
a low serum hepcidin (<14.5 ng/mL), reflecting depleted 
iron stores, and an elevated soluble transferrin receptor 
(sTfR,  ≥ 1.59 mg/L), a marker of reduced cytosolic iron 
less sensitive to inflammation driven perturbation. An 
isolated low hepcidin or elevated sTfR were evident in 
9% and 29%, respectively, of these patients, whereas 37% 
exhibited both laboratory features. While their reported 
prevalence of ID is similar to that seen in our much 
larger population, a French group also examined ID and 
inflammatory biomarkers in a relatively small acute HF 
cohort.27 Serum hepcidin and sTfR levels were available 
for 41 patients. Based on the diagnostic criteria for these 
parameters outlined above, 34 (83%) exhibited ID on 
admission, with a trend towards increasing hepcidin and 
reducing sTfR levels by day 30. There was a weak correla-
tion between changes in ferritin and TSAT status against 
sequentially assessed activity of a range of inflammatory 
markers, not evident for hepcidin and sTfR. These obser-
vations confirm the dynamic nature of conventionally 
perceived iron status and inflammatory responses which 
flux through the early phase and resolution of acute HF.
Once ID is diagnosed in those with HF, treatment needs 
to be considered. As demonstrated in the IRONOUT 
HF study, oral iron supplementation is seemingly inef-
fective.28 Alternatively, the use of intravenous (IV) iron 
therapy appears to be beneficial.29 30 Both the ESC and US 
guidelines propose that this treatment should be offered 
in symptomatic patients with HFrEF and ID,7 31 these 
recommendations based primarily on two major studies 
examining the effects of IV ferric carboxymaltose in 
chronic HFrEF patients, the FAIR- HF and CONFIRM- HF 
trials.29 32
The efficacy and safety of IV iron for those with acute 
HF and ID are still uncertain, but two studies in progress 
may provide clarification. Akin to the clinical population 
analysed in this study, the multinational AFFIRM- AHF 
study (NCT02937454) will assess a composite endpoint 
of HF rehospitalisation and cardiovascular death in 
1100 HFrEF patients (EF <50%) with acute HF and ID, 
treated with IV ferric carboxymaltose. In the UK, the 
IRONMAN study (NCT02642562) will compare cardio-
vascular mortality in 1300 HFrEF patients (EF <45%) 
and ID treated with IV iron, as isomaltoside 1000, against 
placebo. Eligibility criteria include acute HF inpatients 
<48 hours before discharge, or those within 6 months of a 
previous HF admission.
copyright.
 on June 10, 2020 at S
w
ansea U
niversity. P
rotected by
http://openheart.bm
j.com
/
O
pen H
eart: first published as 10.1136/openhrt-2019-001153 on 11 M
arch 2020. D
ow
nloaded from
 
7Beattie JM, et al. Open Heart 2020;7:e001153. doi:10.1136/openhrt-2019-001153
Heart failure and cardiomyopathies
ID may be particularly important in those with HFpEF.33 
The FAIR- HFpEF study (NTC03074591) is underway to 
assess responses to IV ferric carboxymaltose in ambula-
tory HFpEF patients (EF ≥45%) with ID, some patients 
recruited within 12 months of hospitalisation.
study stRengtHs And lIMItAtIOns
The main strength of our study is that our analyses are 
based on data arising from everyday practice, collated 
for almost 80 000 adult patients, admitted with HF to 177 
different hospital sites over a single calendar year and 
constituting all such clinical activity across England over 
that period. This appears to be the first study to systemati-
cally evaluate HES data relating to ID/IDA in this clinical 
population, and to determine outcomes related to these 
comorbidities.
However, given the complexity of the typically multi-
morbid HF population, we cannot presume a causal 
relationship for ID or IDA and the disparities we have 
described between the patient groups with and without 
these documented diagnoses. It is possible that such 
haematology features are to some extent surrogate 
markers of those with greater activation of the renin- 
angiotensin- aldosterone system and increased levels of 
proinflammatory cytokines, and likely therefore to have a 
more complicated clinical course.
There are some potential limitations to our study. 
Although HES coding is considered relatively accurate,11 
we acknowledge that the quality of data subject to analysis 
was dependent on the expertise of local clinicians in diag-
nosing HF and ID/IDA with subsequent correct coding 
for these conditions, over which we have no means of 
adjudication. We have no information on how compre-
hensively this admitted HF cohort was screened for these 
comorbidities, which laboratory tests were employed and 
their timing in those subject to investigation, or whether 
these conditions were pre- existing or newly diagnosed. 
It is likely that a range of laboratory test abnormalities 
will have been evident in those investigated, reflecting 
nuanced differences in their individual health status, 
but to some extent ID and IDA also represent a clinical 
continuum, and in the absence of specific information 
on laboratory data, and given that >26% of patients were 
coded for both ID and IDA, we felt that amalgamating this 
patient data under a single descriptor as ‘ID/IDA’ was a 
realistic approach. Similarly, incorporating HES coding 
as D649 (anaemia, unspecified), may be regarded as a 
confounder, but we have explained our rationale above, 
and our results suggest that no ensuing excess diagnosis of 
ID/IDA emerged compared with previous studies. Finally 
we have no knowledge of the nature or effectiveness of 
any relevant therapy provided to these HF inpatients to 
determine whether or not this might have affected the 
observed study metrics or outcomes. This paper has been 
written on the assumptions of the best available data and 
a reasonable degree of appropriate clinical practice.
COnClusIOn
Based on analyses of the nationally accredited HES data-
base, we have demonstrated that, for the calendar year 
April 2015 through March 2016, ID or IDA appeared to 
be relatively common comorbidities, impacting a signif-
icant proportion of an unselected clinical cohort repre-
senting all adults admitted to hospitals in England with 
HF, of whom more than 90% exhibited an acute HF 
syndrome. The results of this study emanate from the 
real- world clinical milieu, beyond the bounds of clinical 
trials, and as illustrated in the contemporaneous data 
from the NHFA, many patients would have been treated 
by non- specialists who ascertained and documented 
these accompanying conditions. As evidence accrues to 
address other knowledge gaps regarding the accuracy 
of diagnostic testing and effective therapy for ID or IDA 
across the spectrum of acute and chronic HF, including 
the refinement of iron repletion protocols and the emer-
gence of other novel treatment modalities, it is incum-
bent on us as clinicians to ensure robust screening strate-
gies and treatment regimens are in place, consistent with 
evolving national and international guidelines.34This may 
improve outcomes for affected individuals and decrease 
the financial burden on health economies.
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